Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income (2016 - 2025)

Historic Net Income for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.0 million.

  • Rocket Pharmaceuticals' Net Income rose 2414.68% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 745.13%. This contributed to the annual value of -$266.8 million for FY2024, which is 412.81% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Net Income stood at -$52.0 million, which was up 2414.68% from -$71.1 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Net Income peaked at -$33.8 million during Q2 2021, and registered a low of -$71.9 million during Q2 2024.
  • For the 5-year period, Rocket Pharmaceuticals' Net Income averaged around -$57.9 million, with its median value being -$61.6 million (2024).
  • Examining YoY changes over the last 5 years, Rocket Pharmaceuticals' Net Income showed a top increase of 2753.09% in 2021 and a maximum decrease of 7122.35% in 2021.
  • Rocket Pharmaceuticals' Net Income (Quarter) stood at -$43.9 million in 2021, then plummeted by 55.43% to -$68.3 million in 2022, then rose by 7.86% to -$62.9 million in 2023, then rose by 2.2% to -$61.6 million in 2024, then grew by 15.5% to -$52.0 million in 2025.
  • Its Net Income was -$52.0 million in Q3 2025, compared to -$71.1 million in Q2 2025 and -$63.5 million in Q1 2025.